Toronto, Ontario, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Luminar Media Group, Inc., (Luminar, OTCMKTS: LRGR), reports that development of the working prototype for TherOZap™ is progressing well and expected to be completed in 4 to 6 weeks. On December 8, 2016, the Company and The Jenex Corporation announced that TherOZap™ device utilizing proprietary features would be tested against the Zika and West Nile Virus. Jenex is now in the final stages of design work which includes technical advances such as the selection of optimal components and form factor. Chris Cook, CEO and Chairman of Luminar Media Group, Inc., (Luminar, OTCMKTS: LRGR), and global licensee for TherOZap™ outside of Canada comments: “The possibility that this technology may provide an opportunity to mitigate the global risks associated with mosquito borne diseases, such as Zika, is exciting. We are optimistic that testing of TherOZap™ technology will indicate a positive effect at reducing the harm associated with the Zika virus.” The Company would like to caution that the TherOZap™ device may not be effective at all against the Zika and West Nile Virus.
The company expects to initiate testing of a prototype by a world renowned scientific research lab against the Zika and the West Nile virus towards the end of the first quarter of 2017. Testing would be comprised of in-vitro tests to determine if TherOZap™ is effective in inactivating both the Zika and West Nile virus and potentially other mosquito borne diseases. In addition, the lab testing will determine any anti-viral, anti-microbial and anti-inflammatory benefits of the technology. The TherOZap™ device will be completely portable handheld device. Images of the device will be provided on the Company’s website upon completion of the working prototypes.
Rob Fia, Jenex CEO commented:
“We are pleased with the progress of development of the TherOZap™ device and the exciting new features we’ve added to the device. Jenex is truly a leader and early mover in this space.”
Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.
Jenex continues to further develop, and explore other applications, for its platform technology. If you would like to stay informed on the development of TherOZap™ please visit
www.therozap.com
About Jenex
Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex’s philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary thermal therapy technology uses heat and light energy to deliver effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (NEX: JEN.H). For more information visit:
www.thejenexcorporation.com or www.interceptcs.com
About Luminar:
The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries. Luminar will bring this expertise to the TherOZap™ trade name and is developing a global marketing strategy. Initial efforts will focus on launching its innovative therapy device in the United States with additional markets to follow closely. The company was started by entrepreneurs who can identify new tools to communicate with a target audience. At Luminar, we embrace the challenge of the constantly evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm.
Forward-Looking Statements
This news release contains forward-looking statements about our business, or financial condition and prospects, that reflect our assumptions and beliefs based on information currently available. The Company can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this news release, words such as "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including risks discussed in the company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.
Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.